Arca
Skip to content

Multiple system atrophy

Drug research and approvals for multiple system atrophy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 17, 2026, 95 studies of multiple system atrophy are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, and FDA has 0 approved and 9 open orphan designations naming it.

  • Recruiting worldwide: 95
  • Trials authorized in Canada: 2
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 95 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

2 approved, 5 in phase 3, 12 in phase 2, 1 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Droxidopa, Ioflupane

Verdiperstat
Phase 3 Myeloperoxidase inhibitor
Rifampin
Phase 3 Bacterial DNA-directed RNA polymerase inhibitor
Riluzole
Phase 3 Sodium channel alpha subunit blocker
Ampreloxetine
Phase 3 Norepinephrine transporter inhibitor
Exenatide
Phase 2 Glucagon-like peptide 1 receptor agonist
Fluoxetine
Phase 2 Serotonin transporter inhibitor
Lithium carbonate
Phase 2 Inositol-1(or 4)-monophosphatase 1 inhibitor
Sirolimus
Phase 2 FK506-binding protein 1A inhibitor
Insulin human
Phase 2 Insulin receptor agonist
Human immunoglobulin g
Phase 2 Replacement therapy, immunomodulatory effects
Rasagiline
Phase 2 Monoamine oxidase B inhibitor
Safinamide
Phase 2 Monoamine oxidase B inhibitor
Inosine
Phase 2
Amlenetug
Phase 2
Indenebart
Phase 2
PBT-434
Phase 2
Pseudoephedrine
Early phase 1 Norepinephrine transporter releasing agent

How Its Trials Ended

179 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 26 whose ending is known, 31% met their primary endpoint, 8% missed it and 62% stopped early.

  • Ongoing7542%
  • Completed, result not reported6134%
  • Status unknown179%
  • Met its primary endpoint84%
  • Stopped: other or unclear53%
  • Stopped: funding42%
  • Stopped: enrollment or feasibility32%
  • Missed its primary endpoint21%
  • Stopped: lack of efficacy21%
  • Stopped: sponsor or business decision21%

Trials Authorized in Canada

Newest first; search them all in Canada trials
Dec 13, 2024Interventional, randomized, double-blind, placebo-controlled, optional open-label extension trial of lu af82422 in participants with multiple system atrophyLU AF82422H. Lundbeck A/SOngoing
Jul 12, 2023A phase 3, multi-center, randomized withdrawal and long-term extension study of ampreloxetine for the treatment of symptomatic neurogenic orthostatic…Ampreloxetine (TD-9855)Theravance Biopharma Ireland LimitedPending

FDA Orphan Designations

Approved first, then open designations, newest first
Mar 16, 2025ExidavnemabTreatment of multiple system atrophyBioArctic ABDesignated
Apr 30, 2024Human recombinant, monoclonal antibody (mAb) of the IgG1…Treatment of multiple system atrophy (MSA)Lundbeck Pharmaceuticals LLCDesignated
Oct 3, 2023N-(4-Methyl-3-(4-(5-(4-methylisoxazol-5-yl)pyridine-3-yl)pyr…Treatment of Multiple System AtrophyABLi Therapeutics, Inc.Designated
May 9, 2023AmpreloxetineTreatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophyTheravance Biopharma Ireland LimitedDesignated
Sep 1, 20223-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazoleTreatment of Multiple System AtrophyTeva Branded Pharmaceutical Products R&D, Inc.Designated
Jul 1, 20222-[[(4-Methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-…Treatment of Multiple System Atrophy (MSA)Dasher Neuroscience Inc.Designated
Feb 15, 2019VerdiperstatTreatment of multiple system atrophy (MSA).Biohaven Pharmaceuticals, Inc.Designated
Jan 29, 20195,7-Dichloro-2-((ethylamino)methyl)-8-hydroxy-3-methylquinaz…Treatment of multiple system atrophyAlterity Therapeutics, LimitedDesignated
Jan 26, 201518Fluorine-N-3-Fluoropropyl-2beta-carbomethoxy-3beta-(4-iodo…Diagnostic to be used in the management of multiple system atrophy (MSA)Advanced Imaging Projects, LLCDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.